Fund Evaluation Group’s Caris Life Sciences CAI Stock Holding History

Fund Evaluation Group’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.53M	Buy	+48,923	New	+$1.1M	0.04%	59

Other funds holding CAI

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

Zevenbergen Capital Investments Edmonds, Washington $4.37B AUM 52.9% 1-Year Est. Return

Fund Evaluation Group's CAI Position: Q3 2026 in Review

Fund Evaluation Group opened a new position in Caris Life Sciences (CAI) in Q3 2026: 48,923 shares worth $1.53M. The stake represents 0.04% of the portfolio and ranks #59 among its holdings.

166 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

Fund Evaluation Group held 48,923 shares of Caris Life Sciences worth $1.53M as of Q3 2026.
Caris Life Sciences was a new Fund Evaluation Group position in Q3 2026.
Caris Life Sciences made up 0.04% of Fund Evaluation Group's portfolio in Q3 2026, its #59 holding.
166 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on Fund Evaluation Group's 13F filing for Q3 2026, filed 5 Nov 2026.